Zogenix Inc. (Nasdaq: ZGNX) reported upbeat results from a Phase 3 study of ZX008 to treat a form of epilepsy which sent shares of rival GW Pharmaceuticals (Nasdaq: GWPH) plummeting $10.78 to close at $101.49. Zogenix stock more than doubled by leaping $22.17 to close at $35.05.
Zogenix reports upbeat study results
September 29, 2017 at 19:06 PM EDT
